Industry
Biotechnology
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from
November 25, 2024 | 10:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 1:42 pm
Portfolio Pulse from Benzinga Newsdesk
October 11, 2024 | 8:38 pm
Portfolio Pulse from Vandana Singh
October 10, 2024 | 6:43 pm
Portfolio Pulse from Avi Kapoor
October 10, 2024 | 1:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 11:20 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.